Propanc Biopharma (PPCB) Total Non-Current Liabilities (2013 - 2025)
Propanc Biopharma (PPCB) posted quarterly Total Non-Current Liabilities of $35249.0 for Q4 2025, down 57.18% year-over-year from $82328.0 in Q4 2024, and down 16.23% quarter-over-quarter from $42080.0 in Q3 2025.
Propanc Biopharma (PPCB) Total Non-Current Liabilities (2013 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Total Non-Current Liabilities for 13 consecutive years, with $35249.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 57.18% year-over-year to $35249.0; the TTM figure through Dec 2025 stood at $35249.0 (down 57.18% YoY), while the FY2025 annual figure was $147376.0, up 151.31% from the prior year.
- Total Non-Current Liabilities slipped to $35249.0 in Q4 2025 per PPCB's latest filing, from $42080.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $3.1 million in Q1 2022 and bottomed at $19278.0 in Q2 2023.
- Historically, Total Non-Current Liabilities has averaged $750490.8 across 5 years, with a median of $53756.0 in 2024.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities soared 14759.23% — and 2023, when it tumbled 99.19%.
- Propanc Biopharma's Total Non-Current Liabilities stood at $2.8 million in 2021, then tumbled by 98.9% to $30885.0 in 2022, then surged by 40.05% to $43255.0 in 2023, then soared by 90.33% to $82328.0 in 2024, then tumbled by 57.18% to $35249.0 in 2025.
- Business Quant data shows PPCB's Total Non-Current Liabilities at $35249.0 in Q4 2025, $42080.0 in Q3 2025, and $147376.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 35,249.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 35,249.00 |
| Sep 30, 2025 | 42,080.00 |
| Jun 30, 2025 | 147,376.00 |
| Mar 31, 2025 | 93,913.00 |
| Dec 31, 2024 | 82,328.00 |
| Sep 30, 2024 | 70,485.00 |
| Jun 30, 2024 | 58,642.00 |
| Mar 31, 2024 | 48,870.00 |
| Dec 31, 2023 | 43,255.00 |
| Sep 30, 2023 | 36,517.00 |
| Jun 30, 2023 | 19,278.00 |
| Mar 31, 2023 | 24,939.00 |
| Dec 31, 2022 | 30,885.00 |
| Sep 30, 2022 | 39,363.00 |
| Jun 30, 2022 | 42,319.00 |
| Mar 31, 2022 | 3.06 Mn |
| Dec 31, 2021 | 2.82 Mn |
| Sep 30, 2021 | 2.31 Mn |
| Jun 30, 2021 | 3.03 Mn |
| Mar 31, 2021 | 2.98 Mn |